The article focuses on a study reported by physician Rubens Belfort Jr. which found that increased intraocular pressure (IOP) among patients with diabetic macular edema which resulted from the use of dexamethasone intravitreal implant Ozurdex was well-managed with medication and has no effect on visual and anatomic outcomes.